Table 4.
HLA-DRB1*/HLA-DRB1* genotypes distribution in patients with severe DR and patients without DR
| HLA-DRB1*/HLA-DRB1* | Patients with severe DR N = 117 | Patients without DR N = 117 | OR | (CI) | p | ||
|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | ||||
| HLA-DRB1*03/HLA-DRB1*03 | 13 | (11.11) | 15 | (12.82) | 0.85 | (0.38–1.87) | 0.69 |
| HLA-DRB1*03/HLA-DRB1*04 | 31 | (26.50) | 31 | (26.50) | 1.00 | (0.56–1.79) | 1.00 |
| HLA-DRB1*03/X | 10 | (8.55) | 16 | (13.68) | 0.59 | (0.27–1.36) | 0.21 |
| HLA-DRB1*04/HLA-DRB1*04 | 6 | (5.13) | 5 | (4.27) | 1.21 | (0.36–4.09) | 0.76 |
| HLA-DRB1*04/X | 20 | (17.09) | 20 | (17.09) | 1.00 | (0.51–1.97) | 1.00 |
| HLA-DRB1*09/HLA-DRB1*03 | 3 | (2.56) | 4 | (3.42) | 0.74 | (0.16–3.40) | 0.70 |
| HLA-DRB1*09/HLA-DRB1*04 | 0 | (0.00) | 1 | (0.85) | NA | ||
| HLA-DRB1*09/HLA-DRB1*09 | 0 | (0.00) | 0 | (0.00) | NA | ||
| HLA-DRB1*09/X | 1 | (0.85) | 5 | (4.27) | 0.19 | (0.02–1.68) | 0.10 |
| HLA-DRB1*13/HLA-DRB1*13 | 0 | (0.00) | 0 | (0.00) | NA | ||
| HLA-DRB1*13/HLA-DRB1*03 | 3 | (2.56) | 1 | (0.85) | 3.05 | (0.31–29.78) | 0.31 |
| HLA-DRB1*13/HLA-DRB1*04 | 7 | (5.98) | 5 | (4.27) | 1.42 | (0.44–4.63) | 0.55 |
| HLA-DRB1*13/X | 10 | (8.55) | 2 | (1.71) | 5.37 | (1.15–25.09) | 0.02 |
| DRX/DRX | 13 | (11.11) | 12 | (10.26) | 1.09 | (0.48–2.51) | 0.83 |
Bold represents statistical significance (p < 0.05) before Bonferroni correction
p value required for significance after Bonferroni correction 0.004
DR diabetic retinopathy; N number of individuals; OR odds ratio; CI confidence interval; NA non applicable; DRX any haplotype other than HLA-DRB1*03, HLA-DRB1*04, HLA-DRB1*09 or HLA-DRB1*13